First Time Loading...

Allergy Therapeutics PLC
LSE:AGY

Watchlist Manager
Allergy Therapeutics PLC Logo
Allergy Therapeutics PLC
LSE:AGY
Watchlist
Price: 2.875 GBX Market Closed
Updated: May 4, 2024
Section:
 

Wall Street
Price Targets

AGY Price Targets Summary
Allergy Therapeutics PLC

Wall Street analysts forecast AGY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AGY is 16.11 GBX .

AGY Lowest Forecast
Wall Street Target
Not Available
AGY Average Forecast
Wall Street Target
16.11 GBX
460% Upside
AGY Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
16.11 GBX
460% Upside
Highest
Price Target
Not Available
Allergy Therapeutics PLC Competitors:
Price Targets
600479
ZhuZhou QianJin Pharmaceutical Co Ltd
32% Upside
002773
Chengdu Kanghong Pharmaceutical Group Co Ltd
11% Upside
FULC
Fulcrum Therapeutics Inc
74% Upside
H
243070
Huons Co Ltd
70% Upside
600479
ZhuZhou QianJin Pharmaceutical Co Ltd
32% Upside
002773
Chengdu Kanghong Pharmaceutical Group Co Ltd
11% Upside
FULC
Fulcrum Therapeutics Inc
74% Upside
H
243070
Huons Co Ltd
70% Upside
002365
Qianjiang Yongan Pharmaceutical Co Ltd
129% Upside
G
002275
Guilin Sanjin Pharmaceutical Co Ltd
11% Upside
CIPLA
Cipla Ltd
1% Upside
300006
Chongqing Lummy Pharmaceutical Co Ltd
272% Upside

Revenue
Forecast

Revenue Estimate
Allergy Therapeutics PLC

For the last 8 years the compound annual growth rate for Allergy Therapeutics PLC's revenue is 4%. The projected CAGR for the next 2 years is 21%.

4%
Past Growth
21%
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Allergy Therapeutics PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
25%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Allergy Therapeutics PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-64%
Average Miss
What are analyst estimates?

See Also

Summary
AGY intrinsic value, competitors valuation, and company profile.
DCF Valuation
AGY stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AGY stock valuation using valuation multiples.
Wall Street Estimates
AGY price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AGY stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is AGY's stock price target?
Price Target
16.11 GBX

According to Wall Street analysts, the average 1-year price target for AGY is 16.11 GBX .

What is Allergy Therapeutics PLC's Revenue forecast?
Projected CAGR
21%

For the last 8 years the compound annual growth rate for Allergy Therapeutics PLC's revenue is 4%. The projected CAGR for the next 2 years is 21%.

ALPHA SPREAD
Join more than 134,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.